In The Lancet Oncology, Brian Rini and colleagues report the results of TIVO-3, a phase 3, multicentre, randomised, controlled, open-label trial comparing tivozanib, a selective VEGF receptor (VEGFR) tyrosine kinase inhibitor, with sorafenib, an earlier-generation tyrosine kinase inhibitor, as third-line or fourth-line therapy in patients with advanced, clear-cell, renal cell carcinoma. Tivozanib inhibits VEGFR1, VEGFR2, and VEGFR3, similar to axitinib, a drug previously compared with sorafenib as second-line therapy in mostly patients who progressed after VEGFR tyrosine kinase inhibitor or cytokine treatment. Progression-free survival in that study was 6·7 months with axitinib compared with 4·7 months with sorafenib (HR 0·66, 95% CI 0·54–0·81; p<0·0001). Patients had fewer lines of therapy than those in the study by Rini and colleagues, and no overall survival benefit was observed for axitinib.

中文翻译：

---

晚期肾癌的测序治疗。

在柳叶刀肿瘤学中，Brian Rini和同事报告了TIVO-3（一项三期，多中心，随机，对照，开放标签试验）的结果，该试验将选择性VEGF受体（VEGFR）酪氨酸激酶抑制剂替沃扎尼与早期酪氨酸激酶索拉非尼进行了比较抑制剂，作为晚期，透明细胞，肾细胞癌患者的三线或四线治疗药物。替诺扎尼抑制VEGFR1，VEGFR2和VEGFR3的作用类似于阿西替尼，后者是以前与索拉非尼作第二线治疗的药物，在大多数接受VEGFR酪氨酸激酶抑制剂或细胞因子治疗后进展的患者中。在该研究中，阿西替尼的无进展生存期为6·7个月，而索拉非尼为4·7个月（HR 0·66，95％CI 0·54-0·81； p <0·0001）。患者的疗法比Rini及其同事的研究少，